Celldex Therapeutics Inc (O:CLDX) which has been building momentum since late-October, broke out of its bullish consolidation on massive volume, on news that its Rintega brain cancer vaccine reduced the risk of death from the disease by 47 percent in a 73 patient randomized study. Plus, the survival rate at 2 years was 25% for patients given the vaccine versus none in the control group, so I was motivated to buy more shares. This move broke the stock out of a triple top resistance zone that contained the upmove since August. From a technical standpoint, daily technical indicators are looking bullish. The MACD is above its signal line and is moving up in positive territory. CMF is also positive and RSI has moved above its 60% level. On longer-term daily chart, the stock is trading below its 100-day and 200-day EMAs but above its rising 50-day EMA. The short-term bull market is intact, despite being in a bear market in the medium-term. I think the stock next week can easily re-visit its 200-day EMA at $18.48, if not higher. Based on Friday's news, I expect upgrades coming soon.
